-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

3352 Survival of Patients with Multiple Myeloma Treated with Bortezomib-Based Triplets and Autologous Hematopoietic Stem Cell Transplant As First Line in Latin America

Program: Oral and Poster Abstracts
Session: 652. Multiple Myeloma: Clinical and Epidemiological: Poster II
Hematology Disease Topics & Pathways:
Research, Clinical Research, real-world evidence
Sunday, December 10, 2023, 6:00 PM-8:00 PM

Camila Peña, MD1, Virginia Bove2,3*, Eloisa Riva4*, Patricio Duarte5*, Cesar Augusto Samanez-Figari, MD6*, Cristian M Seehaus, MD7*, Luz Tarin-Arzaga, MD8*, Seisha Alana Von Glasenapp, MD9*, Rodrigo Meneces Bustillo, MD10*, Jule F Vasquez, MD11, Marcos Hernandez12*, Claudia Shanley, MD13*, Moisés Manuel Gallardo-Pérez, MD, MSc14,15*, Guillermo José Ruiz-Arguelles, FRCP14,16, Romina Mariano, MD17*, Virginia Gilli18*, David Israel Garrido, MD19*, Patricia Graffigna, MD20*, Natalia Paola Schutz, MD21 and Dorotea Fantl, MD22

1Hospital Del Salvador, Santiago, Chile
2Hospital Central de las FF.AA., Mintevideo, Uruguay
3Centro de Asistencia de la Agrupación Médica de Pando, Montevideo, Uruguay
4Clinical Hospital Dr. Manuel Quintela De Clinicas, Montevideo, Uruguay
5CEMIC, Buenos Aires, Argentina
6AUNA, Lima, Peru
7Hospital Italiano de Buenos Aires, Buenos Aires, ARG
8HU UANL, Monterrey, YU, MEX
9HCIPS, Asuncion, AL, PRY
10Sanatorio Allende, Córdoba, Argentina
11Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru
12Metropolitano del norte universidad de Carabobo, Caracas, VEN
13Hospital Británico Buenos Aires, Bueno Aires, Argentina
14Universidad Popular Autónoma del Estado de Puebla, Puebla, PU, Mexico
15Investigación Clínica, Centro de Hematología y Medicina Interna, Clínica Ruiz, Puebla, MEX
16Centro De Hematologia Medicina Interna, Puebla, Pue, Mexico
18Hospital San Martín, Parana, Argentina
19Hospital de Clinicas, Montevideo, URY
20Hospital del Salvador, Santiago, CHL
21Hematology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
22Hospital Italiano de Buenos Aires, Buenos Aires, BA, ARG


In transplant-eligible newly diagnosed multiple myeloma (NDMM), triplet combinations including proteasome-inhibitors and immunomodulators are the backbone of induction therapy before autologous stem cell transplant (ASCT). Post-ASCT maintenance with lenalidomide is the standard of care. This approach yields deep responses and long overall survival.

In Latin America (LATAM) there is scarce data about the outcome of bortezomib-based triplets and ASCT.

The aim of this study was to evaluate overall survival (OS) in Latin American transplant-eligible NDMM patients induced with bortezomib-based triplets and ASCT.


Retrospective international multicenter cohort study. Patients older than 18 years with MM, who received bortezomib-based triplets followed by ASCT as first line, between 2010 and 2022 were analyzed.

Data were collected from clinical records in a standardized report form. We analyzed clinical characteristics at diagnosis and frontline therapy outcomes. Descriptive statistics were performed. Comparisons of characteristics between groups were made using the Chi-square test, Student´s T-test and ANOVA, as appropriate. Survival analysis was performed using Kaplan-Meier curves, comparisons between groups by Log Rank method, and calculations of the risk relationships by Cox regression. Statistical analysis was performed by using IBM SPSS version 25.0.


A total of 279 patients with NDMM were included, 124 from Argentina, 20 from Chile, 30 from Mexico, 20 from Paraguay, 43 from Peru, 33 from Uruguay, and 9 from Venezuela. Median age was 57 years (range 29-75) with a male predominance (54.8%). Most patients (58%) were treated in private centers. 56.1% were IgG subtype, 24.8% IgA and 17.3% light chain MM. According to the ISS, 69.2% were classified as ISS II or III. Bone disease was the most frequent myeloma-defining events (75.9%), followed by anemia (61.4%), renal failure (24.2%), and hypercalcemia (20.1%). Fluorescence in situ hybridation (FISH) analysis was performed in 53.4% of patients (only 41% with plasma cell sorting), del17p was the most frequent anomaly found (17.4%), followed by t(4;14) (6%), and t(14;16) (2%).

The most frequently used induction regimen was cyclophosphamide-bortezomib-dexamethasone (CyBorD) (38.7%), followed by bortezomib-thalidomide-dexamethasone (VTD) (33.7%), and bortezomib-lenalidomide-dexamethasone (VRD) (27.6%). Very good partial remission (VGPR) or better was achieved in 88.3% for VRD, 81.9% for VTD, and 76.8% for CyBorD (p=0.138). Median time from diagnosis to ASCT was 261.5 days. Only 7 patients received tandem ASCT as first-line consolidation. Maintenance treatment was administered to 88.2% of patients and was based on lenalidomide, thalidomide, bortezomib, and lenalidomide+bortezomib in 67.9%, 16.3%, 8.9% and 3.3%, respectively. Treatments and responses are shown in detail in Table 1.

With a median follow-up of 45 months (range 7-140), median progression-free survival (PFS) was 33 months (95% CI, 26.7 – 39.3). Median PFS according to treatment was 21 months (95% CI, 14.3 – 27.7) for VRD, 35 months (95% CI, 22.2 – 47.8) for VTD, and 36 months (95% CI, 28 – 44) for CyBorD, p=0.004. Median OS of the whole cohort was not reached (NR), and 86% at 45 months; 75 months for VRD (95% CI, 44 – 106), and NR for CyBorD and VTD (p=0.284) (Figure 1).

In the multivariate analysis hypercalcemia (p=0.01) and extramedullary disease (p=0.03) were the only independent risk factors.


FISH was performed only in half of our patients, and the majority without plasma cell sorting. The main used regimen was CyBorD. Although better PFS was obtained with CyBorD, no significant differences in responses or OS were found between VRD, VTD or CyBorD. The reason why VRD PFS and OS were lower merits further study. We report a high rate of maintenance treatment.

Disclosures: Peña: Janssen: Other: Congress Travel expenses.

*signifies non-member of ASH